Inspire Medical Systems, Inc. (INSP)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 2
in 53 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Inspire Medical Systems beat consensus on both revenue and adjusted EPS in the second fiscal quarter of 2026, based on preliminary results reported August 3, with the operating segment generating about $200.6 million of revenue. Revenue fell about 8% to about $200.6 million from about $217.1 million a year ago, but still topped the $194.7 million estimate by about 3%; adjusted EPS of $0.14 was down about 69% from $0.45 a year ago and topped the -$0.24 estimate by about 159%. Gross profit reached about $171.5 million and gross margin held near 86%, while operating cash flow was about $23.2 million. Next-period consensus calls for EPS of $0.12 on revenue of $203.3 million.
About Inspire Medical Systems, Inc.
Inspire Medical Systems, Inc. develops and commercializes minimally intrusive therapies for obstructive sleep apnea, operating in healthcare as a maker of medical devices. Listed on the NYSE as INSP, the company generates revenue from its neurostimulation platform, with $912.0 million reported for FY2025.
Today's Snapshot
Yesterday INSP rose 7.0% to 66.48.
Trading Volume
Above 10d avg 508.4K
1.1M
vs S&P 500 Today
Strong Outperformance
+7.46%
Updated: September 10, 2026 at 12:15 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$56.03 - $65.73Buy
- RSI (14)67.46Neutral
- Stochastic %K (14, 3, 3)78.88Neutral
- MACD Level (12, 26)2.34Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.